CIK 0001395937 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 172.4 M | 0 | ||
| Net income (USD) | -73.2 M | -56.0 M | ||
| Diluted EPS (USD/shares) | -3.29 | -2.46 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-08-07 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-04 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-04 | 8-K | 8-K items 2.02,9.01 | 2026-08-04 |
| 2026-07-14 | 8-K | 8-K items 8.01,9.01 | 2026-07-14 |
| 2026-07-09 | 4 | 4 | 2026-07-08 |
| 2026-07-08 | 144 | 144 | |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 144 | 144 | |
| 2026-06-11 | 144 | 144 | |
| 2026-06-10 | 8-K | 8-K items 1.01,2.03,3.02,9.01 | 2026-06-10 |
| 2026-06-10 | 8-K | 8-K items 5.02,5.07,9.01 | 2026-06-10 |
| 2026-06-04 | DEFA14A | DEFA14A | |
| 2026-06-04 | 8-K | 8-K items 1.01,2.03,3.02,8.01,9.01 | 2026-06-03 |
| 2026-06-02 | 4 | 4 | 2026-06-01 |
| 2026-06-02 | 4 | 4 | 2026-06-01 |
| 2026-06-01 | 144 | 144 | |
| 2026-06-01 | 144 | 144 | |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-04-30 | ARS | ARS | 2025-12-31 |
| 2026-04-30 | DEFA14A | DEFA14A | |
| 2026-04-30 | DEF 14A | DEF 14A | 2026-04-30 |
| 2026-04-30 | 10-Q | 10-Q | 2026-03-31 |
| 2026-04-30 | 8-K | 8-K items 2.02,9.01 | 2026-04-30 |
| 2026-04-30 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-03-27 | SCHEDULE 13G/A | SCHEDULE 13G/A |
Forms on file (last 1,000): 4 222, 8-K 114, SC 13G/A 50, 3 32, 10-Q 32, 144 24, SC 13G 20, 424B5 19. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=SNDX (0.002 USD), /gw/filings/filings?ticker=SNDX&form=8-K, /gw/filings/facts?ticker=SNDX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange